CATALAYER NEWS

FDA delays approval decision for Biohaven rare disease drug - BioPharma Dive

Source: BioPharma Dive · 2025-05-15

Full article text is available in the Catalayer news terminal.

MORE FROM BIOPHARMA DIVE
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
2026-07-28
RELATED ON CATALAYER
Related Topics
Biotech & FDA News
RELATED MARKETS
Prediction Markets
New Rihanna Album before GTA VI?50%New Playboi Carti Album before GTA VI?50%Will Jesus Christ return before GTA VI?50%
Open Catalayer terminal for live tracking →